Reshma Kewalramani, M.D.
Reshma Kewalramani, M.D., FASN, joined Vertex in 2017 and is the company’s Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer. In this role, Dr. Kewalramani oversees clinical development, global regulatory affairs, medical affairs, drug safety and other related functions and is responsible for developing, advising and driving execution of Vertex’s clinical development programs.
Prior to Vertex, Dr. Kewalramani spent more than 12 years at Amgen where she held a variety of roles across Research and Development, including as Vice President, Global Clinical Development, Nephrology & Metabolic Therapeutic Area and Vice President, U.S. Medical Organization, a group she established and grew to assume responsibility for the full portfolio of molecules across six therapeutic areas.
Dr. Kewalramani is the industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee and was on the inaugural Board of Directors of the Kidney Health Initiative. She completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Women’s Hospital combined program. Dr. Kewalramani received her medical degree, with honors, from the Boston University School of Medicine and is also an alumnus of the Harvard Business School.